Tucidinostat is named as an intervention in 4 current clinical trials in our China register. 3 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Ou Bai, MD/PHD (2). The most-studied condition is Diffuse Large B-Cell Lymphoma (DLBCL).
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients
NCT06497985 · ClinicalTrials.gov ↗ · Colorectal Cancer
|
Phase 3 | Recruiting | Chipscreen Biosciences, Ltd. | China |
|
Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP
NCT07493109 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma (DLBCL)
|
Phase 3 | Recruiting | Ou Bai, MD/PHD | China |
|
Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL
NCT07493148 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma (DLBCL)
|
Phase 2 | Recruiting | Ou Bai, MD/PHD | China |
|
Chidamide Monotherapy for Intermediate-to-High-Risk Myelodysplastic Syndromes
NCT07616336 · ClinicalTrials.gov ↗ · Myelodysplastic Syndromes
|
Phase 2 | Not yet open | Zhongshan Hospital (Xiamen), Fudan University | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Ou Bai, MD/PHD | 2 |
| Chipscreen Biosciences, Ltd. | 1 |
| Zhongshan Hospital (Xiamen), Fudan University | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 4 | 3 |
A trial with sites in more than one country appears in each of those registers.
4 current trials in our China register name Tucidinostat as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of the 4 trials are recruiting: 3 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Ou Bai, MD/PHD (2), Chipscreen Biosciences, Ltd (1) and Zhongshan Hospital (Xiamen), Fudan University (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Tucidinostat works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Tucidinostat works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Tucidinostat (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.